ES2886495T3 - Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1H-benzoimidazol-5-il]-N-hidroxi-acrilamida y usos de las mismas - Google Patents

Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1H-benzoimidazol-5-il]-N-hidroxi-acrilamida y usos de las mismas Download PDF

Info

Publication number
ES2886495T3
ES2886495T3 ES17793075T ES17793075T ES2886495T3 ES 2886495 T3 ES2886495 T3 ES 2886495T3 ES 17793075 T ES17793075 T ES 17793075T ES 17793075 T ES17793075 T ES 17793075T ES 2886495 T3 ES2886495 T3 ES 2886495T3
Authority
ES
Spain
Prior art keywords
benzoimidazol
butyl
hydroxy
diethylamino
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17793075T
Other languages
English (en)
Spanish (es)
Inventor
David Duncan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lite Strategy Inc
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Application granted granted Critical
Publication of ES2886495T3 publication Critical patent/ES2886495T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES17793075T 2016-05-02 2017-05-01 Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1H-benzoimidazol-5-il]-N-hidroxi-acrilamida y usos de las mismas Active ES2886495T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662330673P 2016-05-02 2016-05-02
PCT/US2017/030414 WO2017192451A1 (en) 2016-05-02 2017-05-01 Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof

Publications (1)

Publication Number Publication Date
ES2886495T3 true ES2886495T3 (es) 2021-12-20

Family

ID=60203321

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17793075T Active ES2886495T3 (es) 2016-05-02 2017-05-01 Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1H-benzoimidazol-5-il]-N-hidroxi-acrilamida y usos de las mismas

Country Status (20)

Country Link
US (2) US10626092B2 (enExample)
EP (2) EP3939966A1 (enExample)
JP (1) JP2019514905A (enExample)
KR (1) KR20190005904A (enExample)
CN (1) CN109414425A (enExample)
AR (1) AR108257A1 (enExample)
AU (1) AU2017261218A1 (enExample)
BR (1) BR112018072439A2 (enExample)
CA (1) CA3022011A1 (enExample)
CL (1) CL2018003109A1 (enExample)
CO (1) CO2018012941A2 (enExample)
EA (1) EA201892341A1 (enExample)
ES (1) ES2886495T3 (enExample)
IL (1) IL262578A (enExample)
MA (1) MA44880A (enExample)
MX (1) MX382095B (enExample)
PH (1) PH12018502296B1 (enExample)
SG (1) SG11201809471UA (enExample)
TW (1) TW201741286A (enExample)
WO (1) WO2017192451A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018157742A1 (zh) * 2017-02-28 2018-09-07 苏州科睿思制药有限公司 Sb-939的盐的晶型及其制备方法和用途
WO2019126282A1 (en) 2017-12-19 2019-06-27 Assia Chemical Industries Ltd. Crystalline polymorphs of pracinostat and pracinostat salts
WO2019149262A1 (zh) * 2018-02-05 2019-08-08 苏州科睿思制药有限公司 Sb-939的晶型及其制备方法和用途
US20230159468A1 (en) 2020-04-22 2023-05-25 Macfarlan Smith Limited Novel forms of pracinostat dihydrochloride

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2291749A1 (fr) 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
CA2135173A1 (en) 1992-05-20 1993-11-25 Bruce E. Witzel Ester derivatives of 4-aza-steroids
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
EP1206265B1 (en) 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
CN1358094A (zh) 1999-07-16 2002-07-10 沃尼尔·朗伯公司 用mek抑制剂治疗慢性疼痛的方法
JP2003504401A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Mek阻害剤を用いる慢性疼痛の治療方法
GB9919558D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
US6541661B1 (en) 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
SK13752001A3 (sk) 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
HUP0400651A2 (hu) 2000-11-07 2004-06-28 Bristol-Myers Squibb Company Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
WO2003000682A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2473505A1 (en) 2002-02-07 2003-08-14 Ellen M. Leahy Novel bicyclic hydroxamates as inhibitors of histone deacetylase
CA2478534A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
CA2478374C (en) 2002-03-13 2009-01-06 Eli M. Wallace N3 alkylated benzimidazole derivatives as mek inhibitors
AU2003231359B2 (en) 2002-04-16 2009-04-30 Teijin Limited Piperidine derivatives having CCR3 antagonism
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7151096B2 (en) 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
MY142589A (en) 2003-09-22 2010-12-15 S Bio Pte Ltd Benzimidazole derivatives : preparation and pharmaceutical applications
WO2005066151A2 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
CA2540459C (en) * 2005-09-08 2014-02-18 S*Bio Pte Ltd Benzimidazole compounds and uses in treating proliferative disorders
PL1937650T3 (pl) * 2005-09-08 2011-11-30 Mei Pharma Inc Związki heterocykliczne
EP2131840B1 (en) 2007-03-07 2018-10-17 MEI Pharma, Inc. Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
EP3662911A1 (en) 2012-10-30 2020-06-10 MEI Pharma, Inc. Combination of azacitidine and pracinostat to treat myelodysplastic syndrome (mds)

Also Published As

Publication number Publication date
US20200317621A1 (en) 2020-10-08
EA201892341A1 (ru) 2019-05-31
CN109414425A (zh) 2019-03-01
BR112018072439A2 (pt) 2019-02-19
EP3452035A1 (en) 2019-03-13
PH12018502296B1 (en) 2022-04-06
KR20190005904A (ko) 2019-01-16
JP2019514905A (ja) 2019-06-06
TW201741286A (zh) 2017-12-01
AR108257A1 (es) 2018-08-01
WO2017192451A1 (en) 2017-11-09
MX2018013349A (es) 2019-02-20
SG11201809471UA (en) 2018-11-29
PH12018502296A1 (en) 2019-07-08
EP3452035A4 (en) 2019-09-25
EP3939966A1 (en) 2022-01-19
AU2017261218A1 (en) 2018-11-29
IL262578A (en) 2018-12-31
US20190152923A1 (en) 2019-05-23
CA3022011A1 (en) 2017-11-09
CO2018012941A2 (es) 2018-12-28
MX382095B (es) 2025-03-13
MA44880A (fr) 2021-03-17
CL2018003109A1 (es) 2019-04-26
US10626092B2 (en) 2020-04-21
EP3452035B1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
ES3034158T3 (en) Novel salt of terphenyl compound
ES3011209T3 (en) Salts of an lsd1 inhibitor
ES2750676T3 (es) Sal de omecamtiv mecarbil y proceso de preparación de la sal
ES2773543T3 (es) Benzoimidazol-2-ilpirimidinas moduladores del receptor de histamina H4
ES2886495T3 (es) Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1H-benzoimidazol-5-il]-N-hidroxi-acrilamida y usos de las mismas
ES2649539T3 (es) Formulaciones farmacéuticas que comprenden formas cristalinas de clorhidrato de (R)-7-cloro-N-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado
JP2015522037A (ja) ベムラフェニブコリン塩の固体形態
US20240228438A1 (en) Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2- hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile
BR112015002923B1 (pt) Compostos antibacterianos, composição farmacêutica e processo de preparação dos mesmos
ES2671608T3 (es) Formas sólidas de 3-(4-nitro-1-oxoisoindolin-2-il)piperidina-2,6-diona
ES2908572T3 (es) Formas cristalinas
ES2784325T3 (es) Formas cristalinas de sales farmacéuticamente aceptables de N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas
KR102783080B1 (ko) [(1S)-1-[(2S,4R,5R)-5-(5-아미노-2-옥소-티아졸로[4,5-d]피리미딘-3-일)-4-하이드록시-테트라하이드로퓨란-2-일]프로필]아세테이트의 고체 형태
ES2384517T3 (es) Procedimiento para la producción de una sal de un aducto de ácido de un compuesto alcalino poliacídico
RU2761825C1 (ru) Соединения дейтерированного дефактиниба и их применение
ES2949414T3 (es) Formas cristalinas de 4-(2-((1R,2R)-2-hidroxiciclohexilamino)benzotiazol-6-iloxi)-N-metilpicolinamida
ES2861050T3 (es) Procedimiento de producción de derivado de tiazol
US20220162185A1 (en) Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
ES2568245T3 (es) Solvatos cristalinos de hidrocloruro de 6-(piperidin-4-iloxi)-2H-isoquinolin-1-ona
WO2020178795A1 (en) [ 18f]-labeled benzothiazole derivative as pet radiotracer
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
HK40076742A (en) Novel salt of terphenyl compound
PT1534667E (pt) Agonistas muscarínicos
BR112017015828B1 (pt) Compostos derivados de pirazolo[3,4-d]pirimidina, composição farmacêutica e combinação compreendendo ditos compostos e uso dos mesmos para o tratamento de leishmaniose
BR122024025362A2 (pt) Formas cristalinas de um inibidor de janus cinase, composição farmacêutica compreendendo as ditas formas cristalinas, seu uso e métodos de medição